APA (7th ed.) Citation

NJ, S., HM, K., NG, D., RS, A., O, K., CD, D., . . . F, R. (2026). Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML. Blood advances. https://doi.org/10.1182/bloodadvances.2026019841

Chicago Style (17th ed.) Citation

NJ, Short, et al. "Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML." Blood Advances 2026. https://doi.org/10.1182/bloodadvances.2026019841.

MLA (9th ed.) Citation

NJ, Short, et al. "Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML." Blood Advances, 2026, https://doi.org/10.1182/bloodadvances.2026019841.